Kardas, P.; Lichwierowicz, A.; Urbański, F.; Szadkowska-Opasiak, B.; Karasiewicz, E.; Lewek, P.; Krupa, D.; Czech, M.
The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis. Pharmaceutics 2021, 13, 1165.
https://doi.org/10.3390/pharmaceutics13081165
AMA Style
Kardas P, Lichwierowicz A, Urbański F, Szadkowska-Opasiak B, Karasiewicz E, Lewek P, Krupa D, Czech M.
The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis. Pharmaceutics. 2021; 13(8):1165.
https://doi.org/10.3390/pharmaceutics13081165
Chicago/Turabian Style
Kardas, Przemysław, Aneta Lichwierowicz, Filip Urbański, Beata Szadkowska-Opasiak, Ewa Karasiewicz, Paweł Lewek, Dominika Krupa, and Marcin Czech.
2021. "The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis" Pharmaceutics 13, no. 8: 1165.
https://doi.org/10.3390/pharmaceutics13081165
APA Style
Kardas, P., Lichwierowicz, A., Urbański, F., Szadkowska-Opasiak, B., Karasiewicz, E., Lewek, P., Krupa, D., & Czech, M.
(2021). The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis. Pharmaceutics, 13(8), 1165.
https://doi.org/10.3390/pharmaceutics13081165
